NASDAQ: TLX
Telix Pharmaceuticals Ltd Stock Forecast, Predictions & Price Target

Analyst price target for TLX

Based on 2 analysts offering 12 month price targets for Telix Pharmaceuticals Ltd

Min Forecast
$22.00+36.73%
Avg Forecast
$22.00+36.73%
Max Forecast
$22.00+36.73%

Should I buy or sell TLX stock?

Based on 2 analysts offering ratings for Telix Pharmaceuticals Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TLX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TLX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TLX stock forecasts and price targets.

TLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-12
lockedlocked$00.00+00.00%2025-01-27

1 of 1

Forecast return on equity

Is TLX forecast to generate an efficient return?

Company
N/A
Industry
140.91%
Market
90.47%

Forecast return on assets

Is TLX forecast to generate an efficient return on assets?

Company
N/A
Industry
32.45%

TLX earnings per share forecast

What is TLX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.52
Avg 2 year Forecast
$0.74
Avg 3 year Forecast
$1.01

TLX revenue forecast

What is TLX's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$821.4M+68.85%
Avg 2 year Forecast
$1.1B+120.72%
Avg 3 year Forecast
$1.3B+162%
TLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TLX revenue growth forecast

How is TLX forecast to perform vs Biotechnology companies and vs the US market?

Company
37.59%
Industry
56.38%
Market
9.68%
TLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TLX$16.09$22.00+36.73%Strong Buy
NUVL$78.24$105.00+34.20%Strong Buy
AXSM$104.10$174.87+67.98%Strong Buy
IONS$35.59$54.38+52.78%Buy
TGTX$36.01$55.00+52.74%Buy

Telix Pharmaceuticals Stock Forecast FAQ

Is Telix Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TLX) stock is to Strong Buy TLX stock.

Out of 2 analysts, 1 (50%) are recommending TLX as a Strong Buy, 1 (50%) are recommending TLX as a Buy, 0 (0%) are recommending TLX as a Hold, 0 (0%) are recommending TLX as a Sell, and 0 (0%) are recommending TLX as a Strong Sell.

If you're new to stock investing, here's how to buy Telix Pharmaceuticals stock.

What is TLX's earnings growth forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Telix Pharmaceuticals's earnings in 2025 is $31,395,597.On average, 4 Wall Street analysts forecast TLX's earnings for 2025 to be $174,056,732, with the lowest TLX earnings forecast at $70,292,142, and the highest TLX earnings forecast at $277,821,323. On average, 4 Wall Street analysts forecast TLX's earnings for 2026 to be $248,532,930, with the lowest TLX earnings forecast at $120,500,815, and the highest TLX earnings forecast at $344,766,220.

In 2027, TLX is forecast to generate $338,071,730 in earnings, with the lowest earnings forecast at $123,848,059 and the highest earnings forecast at $471,961,524.

What is TLX's revenue growth forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual revenue growth rate of 37.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Telix Pharmaceuticals's revenue in 2025 is $492,583,018.On average, 3 Wall Street analysts forecast TLX's revenue for 2025 to be $274,941,353,081, with the lowest TLX revenue forecast at $269,208,861,551, and the highest TLX revenue forecast at $280,164,393,945. On average, 3 Wall Street analysts forecast TLX's revenue for 2026 to be $359,398,030,963, with the lowest TLX revenue forecast at $350,727,662,628, and the highest TLX revenue forecast at $368,565,130,434.

In 2027, TLX is forecast to generate $426,620,749,285 in revenue, with the lowest revenue forecast at $406,740,457,948 and the highest revenue forecast at $453,417,787,381.

What is TLX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TLX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is TLX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TLX price target, the average TLX price target is $22.00, with the highest TLX stock price forecast at $22.00 and the lowest TLX stock price forecast at $22.00.

On average, Wall Street analysts predict that Telix Pharmaceuticals's share price could reach $22.00 by Jun 12, 2026. The average Telix Pharmaceuticals stock price prediction forecasts a potential upside of 36.73% from the current TLX share price of $16.09.

What is TLX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that TLX's EPS will be $0.52 for 2025, with the lowest EPS forecast at $0.21, and the highest EPS forecast at $0.83. On average, analysts forecast that TLX's EPS will be $0.74 for 2026, with the lowest EPS forecast at $0.36, and the highest EPS forecast at $1.03. In 2027, TLX's EPS is forecast to hit $1.01 (min: $0.37, max: $1.41).

What is TLX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TLX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.